ArticleMethods in molecular biology (Clifton, N.J.)2025
DNA Decatenation Catalyzed by Bacterial Topoisomerase IV.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
One of the essential functions of type II topoisomerases is the decatenation (unlinking) of interlinked daughter chromosomes that are formed due to the torsional stress generated by the opening of the double helix during DNA replication. To resolve these intermolecular tangles, type II topoisomerases interact with two separate DNA molecules and pass one through the other. Different topoisomerases can catalyze this reaction with variable efficiency, and decatenation activity can be measured in vitro using purified enzymes and a catenated DNA substrate. The essential decatenation function of type II topoisomerases can also be inhibited by antibacterial and anticancer compounds. This chapter will describe an agarose gel electrophoresis-based assay to measure the decatenation of kinetoplast DNA purified from Crithidia fasciculata by bacterial topoisomerase IV. It will also describe how the assay can be used to monitor the inhibition of decatenation by topoisomerase IV-targeted antibacterial drugs. Finally, the protocols described in this chapter can be easily modified for use with other bacterial and eukaryotic type II topoisomerases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.